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Functional Relevance of AcrB Trimerization in Pump
Assembly and Substrate Binding
Wei Lu, Meng Zhong, Qian Chai, Zhaoshuai Wang, Linliang Yu, Yinan Wei*
Department of Chemistry, University of Kentucky, Lexington, Kentucky, United States of America
Abstract
AcrB is a multidrug transporter in the inner membrane of Escherichia coli. It is an obligate homotrimer and forms a tripartite
efflux complex with AcrA and TolC. AcrB is the engine of the efflux machinery and determines substrate specificity. Active
efflux depends on several functional features including proton translocation across the inner membrane through a proton
relay pathway in the transmembrane domain of AcrB; substrate binding and migration through the substrate translocation
pathway; the interaction of AcrB with AcrA and TolC; and the formation of AcrB homotrimer. Here we investigated two
aspects of the inter-correlation between these functional features, the dependence of AcrA-AcrB interaction on AcrB
trimerization, and the reliance of substrate binding and penetration on protein-protein interaction. Interaction between
AcrA and AcrB was investigated through chemical crosslinking, and a previously established in vivo fluorescent labeling
method was used to probe substrate binding. Our data suggested that dissociation of the AcrB trimer drastically decreased
its interaction with AcrA. In addition, while substrate binding with AcrB seemed to be irrelevant to the presence or absence
of AcrA and TolC, the capability of trimerization and conduction of proton influx did affect substrate binding at selected
sites along the substrate translocation pathway in AcrB.
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Introduction
AcrB is a multidrug transporter in the inner membrane of
Escherichia coli [1–3]. It is a secondary transporter, harvesting the
proton gradient across the inner membrane to drive the efflux of
an array of structurally different compounds out of the cell [1–3].
AcrB exists and functions as a homotrimer and forms a tripartite
complex with outer membrane protein TolC and membrane
fusion protein AcrA. Together they form an efflux machinery that
spans both layers of membranes and the periplasmic space. This
AcrA-AcrB-TolC complex and its homologues are major players
in multidrug resistance in Gram-negative bacteria [4]. AcrB is the
engine of the complex and determines substrate specificity. Crystal
structures of AcrB have been obtained both in the substrate free
and bound states [5–17]. The pathway of substrate entry and exit
has been proposed based on these structures and subsequent
mutational studies [17–25]. Recently, Nikaido and co-workers
have mapped the substrate translocation pathway in AcrB through
a combination of site-directed mutagenesis and fluorescent
labeling [26,27].
Functional features that are critical to AcrB drug efflux include
the proton translocation via the proton relay pathway, substrate
binding and migration through the substrate translocation
pathway, and AcrB trimerization and the interaction with AcrA
and TolC to form a sealed exit path across the periplasm and outer
membrane. Substrate extrusion requires all features to operate
properly. In this study we investigated the effects of each individual
aspect, namely proton relay, interaction with AcrA/TolC, and
trimerization, on substrate binding. While disruptions of interac-
tion with AcrA/TolC and proton relay are easy to realize
experimentally, it was more complicated to create monomeric
AcrB. In a recent study we have constructed such a mutant,
AcrBDloop, which provided us a tool to investigate the functional
role of AcrB trimerization on substrate binding and interaction
with its functional partner AcrA [28].
To create AcrBDloop, residues 211 to 227 in AcrB, which are
part of a long extended loop that is critical for inter-subunit
interaction, were deleted (Figure 1A). Residue 210 was directly
connected to residue 228. The rationale behind the design was
that since this loop is not involved in the packing of the tertiary
structure of AcrB, changes made on the loop should not have a
significant impact on the folding of each subunit. As a summary of
the previous study, we first confirmed AcrBDloop expressed to a
level similar to wild type AcrB but was completely non-functional
[28]. AcrBDloop could be purified similarly to the wild type AcrB
with comparable yield. The secondary structure component of the
mutant was comparable with that of the wild type protein as
revealed by the circular dichroism (CD) spectra. Heat denatur-
ation of the two proteins was monitored at 222 nm using CD and
the two curves superimposed well onto each other, indicating
similar secondary structure stability. Furthermore, we confirmed
AcrBDloop existed as a monomer using Blue Native (BN)-PAGE,
while wild type AcrB is a trimer. We have also confirmed that loop
truncation did not have a significant effect on the overall tertiary
conformation of the periplasmic domain using a disulfide trapping
based method [28,29].
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In this study we examined the relative accessibility of the
substrate translocation pathway under three conditions: in
AcrBDloop which is monomeric; in AcrBD407A which is defective
in proton translocation; and in a DacrABtolC knockout strain where
both AcrA and TolC are absent. Although no drug efflux could
occur under all three conditions, the levels of ‘‘damage’’ to the
efflux machinery were different. In the knockout strain the
structure of AcrB trimer is intact and is capable of drug extrusion.
In AcrBD407A the protein remains as a trimer and still interacts
with AcrA and TolC, although proton relay is disrupted [30–32].
While in AcrBDloop, the protein dissociates into monomers. We
compared substrate binding and penetration in AcrB under these
three conditions. In addition, we examined the interaction of
AcrBDloop with the functional partner AcrA.
Results
Substrate Binding in AcrBDloop
We choose to use the in vivo fluorescent labeling method
developed by Nikaido and co-workers due to its unique advantage
that labeling is conducted in live cell cultures with AcrB still
embedded in the cell membrane. Therefore, the result will better
reflect the actual state of the protein and will not be affected by
artifact from detergent solubilization and protein purification
[26,27]. It has been demonstrated that labeling is highly specific to
Cys in the translocation pathway. Cys introduced at random
locations on the surface of AcrB were not labeled. To investigate
the binding and penetration of substrate in AcrBDloop, we replaced
the two intrinsic Cys with Ala to create CLAcrBDloop and chose to
label 14 sites along the substrate translocation pathway based on
two considerations: First, we expect the level of labeling in
CLAcrBDloop to be equal or weaker than the level of labeling in
trimeric CLAcrB. Therefore, we chose sites that are labeled
strongly in CLAcrB so a clear difference could be observed if
labeling were significantly reduced in CLAcrBDloop. Second, we
selected sites that are distributed evenly along the pathway. The
locations of the chosen residues are shown in Figure 1B. These
residues were color-coded, in which F664, F666, L668 and R717
were at the entrance of the external cleft, D566, E673 and T676
were part of the bottom of the cleft, and Q89, S134, F136, N274,
D276, F617, and R620 were in a deep drug binding pocket. For
each site, a single Cys mutation was introduced into either trimeric
CLAcrB or monomeric CLAcrBDloop and their labeling was
examined in BW25113DacrB strain.
Fluorescent labeling and purification was conducted as
described in Materials and Methods. Briefly, BW25113DacrB cells
containing plasmids encoding different AcrB mutants were
incubated with Bodipy-FL-maleimide. After the removal of excess
dye, cells were lysed for protein purification using metal affinity
chromatography. Purified samples were analyzed using SDS-
PAGE. Representative gel images taken under fluorescent light
before Coomassie staining (F) and under white light after staining
(CB) were shown in Figure 2A. The ratio of labeling at each site
was obtained by dividing the concentration-normalized fluores-
cence signal of the CLAcrBDloop sample by the concentration-
normalized fluorescence signal of the CLAcrB sample as described
in Materials and Methods (Figure 2B). For several sites, including
566C, 664C, 666C, 668C, 676C, and 717C, the level of
fluorescent labeling in CLAcrBDloop were comparable to the level
of labeling in CLAcrB. For the rest of the sites tested, levels of
labeling in CLAcrBDloop were significantly lower than those in
CLAcrB.
Substrate Binding in AcrBD407A
In 2006, two research groups independently reported the
asymmetric structure of AcrB trimer, which supported a confor-
mational cycling model for drug transport [8,12]. In the
asymmetric trimer, one subunit in each trimer bound a drug
molecule. The conformation of each subunit was different and the
binding site located in the periplasmic domain of AcrB. Based on
those different conformations, the subunits were designated as
loose (access), tight (binding) and open (extrusion) state, respec-
tively. A conformational rotation mechanism for drug export has
been proposed. A substrate binds with the subunit at the loose
state, rotates through the tight, and then open state before being
pumped out of the cell. The asymmetric subunits represent
Figure 1. Structure of AcrB. A. Top view of AcrB trimer from the periplasmic side of the membrane. Subunits are color-coded with residues 211 to
227 colored in red. B. Periplasmic domain of AcrB with sites tested in this study highlighted by spheres at the positions of their Ca position. Ca
spheres were colored following the scheme established in an earlier publication with brown, purple, and teal representing entrance to the external
cleft, bottom of the external cleft, and the deep drug binding pocket, respectively [26]. Structure was created from 2DHH.pdb [8].
doi:10.1371/journal.pone.0089143.g001
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different stages of the pumping cycles. Sennhauser et al. used a
Designed Ankirin Repeat Protein (DARPin) to co-crystallize with
AcrB and obtained the asymmetric structure at the highest
resolution of 2.5 Å [13]. The stoichiometry of AcrB-DARPin
complex was 3:2, and the DARPin was shown to stabilize the
intermediates conformation in the transport cycles which support-
ed a rotary mechanism for AcrB drug transport. Energy required
to drive this conformational rotation derives from proton
translocation down its concentration gradient across the inner
membrane. Residue D407 in AcrB is a critical residue on the
proton relay pathway. AcrBD407A was completely inactive due to
the disruption of proton translocation [30,33]. In AcrBD407A each
protomer might be ‘‘frozen’’ into a fixed conformation rather than
rotating through three conformations. Other than that the overall
structure of AcrBD407A was very similar to the structure of wild
type AcrB [30]. It remains as a tightly associated trimer and
interacts with AcrA and TolC [30–32]. In a previous study the
relative levels of labeling in CLAcrBD407A as compared to CLAcrB
had been reported for four sites, N274, D276, F666, and T676,
underlined on Figure 1B [26]. Among the sites tested,
CLAcrBN274C/D407A, CLAcrBD276C/D407A and CLAcrBF666C/D407A
were labeled at the levels of 61%, 42% and 47% of the
corresponding controls CLAcrBN274C, CLAcrBD276C, and
CLAcrBF666C, respectively. No difference in the labeling of
CLAcrBT676C and CLAcrBT676C/D407A was observed.
We found that the levels of labeling of F666 and T676 in
CLAcrBDloop were comparable to the levels of labeling in
CLAcrBD407A. However, the labeling of N274 and D276 was
much less in the monomeric mutant. Furthermore, we tested the
labeling of five additional sites in CLAcrBD407A, including Q89C,
S134C, F617C, R620C, and E673C. These sites were chosen
because they were labeled significantly less in CLAcrBDloop as
compared to in CLAcrB. For sites that were labeled similarly in
monomeric AcrB as compared to wild type AcrB, we expect the
level of labeling would not be affected by the gentler change as a
result of the D407A mutation. Labeling of CLAcrB and
CLAcrBD407A were conducted in MG1655DacrB strain. Represen-
tative gel images taken under fluorescent light before Coomassie
staining (F) and under white light after staining (CB) were shown in
Figure 3A (Lane 2). Labeling of the corresponding sites in CLAcrB
was also conducted in parallel and loaded to the same gel
(Figure 3A, lane C). The ratio of labeling at each site was obtained
by dividing the concentration-normalized fluorescence signal of
the CLAcrBD407A sample by the concentration-normalized fluo-
rescence signal of the CLAcrB sample as described in materials and
method (grey bars, Figure 3B). Overall the levels of labeling in
CLAcrBD407A of all sites tested were significantly higher than the
level of labeling in CLAcrBDloop. When compared to the level of
labeling in CLAcrB, little difference could be observed for sites
Q89C and F617C, and 30–40% differences could be observed for
S134C, R620C and E673C.
Substrate Binding in the Absence of AcrA and TolC
AcrB function as a component of the protein complex together
with AcrA and TolC. No substrate efflux could occur in the
absence of either AcrA or TolC. To further investigate the
correlation between drug efflux and substrate binding, we
examined the labeling of selected sites in a triple knockout strain
lacking chromosomally encoded AcrAB and TolC. In this case
while not functional, the structure of AcrB is intact. We labeled the
same panel of sites as in the case of CLAcrBD407A in MG1655DacrB
(Figure 3A, lane C) and MG1655DacrABtolC (Figure 3A, lane 1).
Labeling of each site in all three samples, including the control
CLAcrB, CLAcrBD407A, and CLAcrB in the triple knockout strain,
were actually conducted in parallel for a better comparison. The
ratio of labeling at each site was obtained similarly as described
above (black bars, Figure 3B). Overall the levels of labeling in the
triple knockout strain of all sites tested were very similar to the
levels of labeling in the control sample, indicating that the absence
of AcrA and TolC did not have a significant effect on substrate
binding and penetration in AcrB.
One potential cause that could have resulted in the lack of
difference in strains of MG1655 DacrB and MG1655DacrABtolC is
the mismatch of expression levels–it is possible that since AcrB was
expressed from a plasmid while AcrA and TolC were from the
chromosomal DNA, the final expression levels of AcrB would be
higher than the level of AcrA and TolC. Therefore, AcrA and
TolC could be deficient even under the control condition. The
chromosomal expression levels of AcrA, AcrB, and TolC in E. coli
strain ZK4 have been examined and the relative molar ratios of
these three proteins were estimated to be 5000–7000:500:1500
[34]. We have also determined the expression level of AcrB from
plasmid pQE70-AcrB under the basal condition to be roughly 16
times of the chromosomal expression level [35]. When AcrB was
expressed from a plasmid there is likely a shortage of AcrA and
TolC. Therefore, we co-expressed AcrA or TolC with AcrB by
Figure 2. Comparison of substrate accessibility of residues
lining up the substrate translocation pathway in monomeric
and trimeric AcrB. A. Representative gel images. For each position
tested, the bottom panel (F) is the fluorescence image before staining
and the top panel (CB) is the image of the same gel after Coomassie
blue stain. Lane 1 and 2 were mutants containing Cys at the indicated
site on the background of CLAcrB and CLAcrBDloop, respectively. CLAcrB
without introduced Cys was used as the negative control (lane WT, con)
to confirm the lack of non-specific labeling. B. Relative percentage of
labeling for each site in CLAcrBDloop relative to CLAcrB. Each experiment
was performed three times. The average value and standard deviation
were shown.
doi:10.1371/journal.pone.0089143.g002
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transforming two compatible plasmids into MG1655DacrB and
examined the effect on labeling at two sites, N274C and S134C.
These two sites were chosen to represent sites for which labeling
were affected by both D407A mutation and the trimer dissocia-
tion, and thus are expected to be more sensitive to changes of
AcrA and TolC concentrations. As shown in Figure 3C, the over-
expression of AcrA and TolC had no observable effect on the level
of fluorescent labeling, further confirmed our previous observation
that the presence or absence of AcrA and TolC did not have a
significant effect on substrate access to the translocation pathway
in AcrB.
Interaction of AcrBDloop with Functional Partner AcrA
Interaction of AcrA with wild type trimeric AcrB and
monomeric AcrBDloop was examined using an established protocol
in literature [36,37]. E. coli cells containing AcrB or AcrBDloop
were treated with a chemical cross-linker dithiobis succinimidyl
propionate (DSP), which has been shown to form covalent linkages
between wild type AcrA and AcrB in E. coli cells. After cross-
linking, cells were lysed and proteins capable of binding to Ni-
NTA resin were purified. AcrA, in the absence of AcrB, could not
be purified from the cell lysate (Figure 4, lane 3). In the presence of
AcrB, a significant AcrA band was visible, indicating that the
interaction between AcrA and AcrB was critical for the detection
of the AcrA band in the purified sample (Figure 4, lane 1). Finally,
when AcrB was replaced with the monomeric mutant AcrBDloop,
the level of co-purified AcrA decreased drastically, indicating that
the interaction between AcrBDloop and AcrA was weaker than the
interaction between the wild type proteins (Figure 4, lane 2).
Effect of Cys Mutation on AcrB Activity
To evaluate the effect of Cys mutation on the efflux activity of
AcrB, we measured the activity of each mutant using a drug
susceptibility assay. The minimum inhibitory concentrations
(MICs) for two well established AcrB substrates, erythromycin
and novobiocin, were listed in Table 1. BW25113DacrB strains
containing a plasmid encoding the wild type AcrB (pQE70-AcrB)
or the empty vector (pQE70) were used as the positive and
negative controls, respectively. The mutants displayed a broad
range of activities. This is not surprising as mutations of residues
lining up the substrate translocation pathway may impact substrate
efflux, some more than others.
Discussion
The triplex efflux system AcrAB-TolC is a key player in
multidrug resistance in E. coli. In this large protein complex, AcrB
is the component that first takes up substrates from the periplasm
and/or inner membrane of the cell [1–3]. Many residues in AcrB
have been found to make direct contact with substrate and line up
the drug translocation pathway [26,27]. For effective efflux, a
substrate molecule has to bind and go through the drug
translocation pathway in the periplasmic domain of AcrB. But
how much does substrate binding and penetration rely on active
efflux? To answer this question, we studied fluorescent labeling of
sites lining up the substrate translocation pathway under three
conditions devoid of active efflux. These conditions differ in the
level of structure impairment in AcrB, and the observed level of
labeling in response of structure changes differed for different sites.
Labeling of 14 sites was examined in this study, and their data are
summarized in Table 1.
The most surprising discovery is the lack of significant response
of the level of labeling to the absence of AcrA and TolC. In other
words, substrate can bind and enter the translocation pathway of
AcrB even without active drug efflux. As discussed above, the three
subunits in an AcrB trimer adopt different conformations that are
intrinsically not equally accessible by the substrates. The
observation that all sites tested could be labeled to similar level
as under the condition with active efflux seemed to suggest that
although substrate were not extruded out of the cell, conversion
between the three conformations was still possible. Since the
Figure 3. Substrate accessibility of residues lining up the
substrate translocation pathway in the triple knockout strain
and in AcrBD407A. A. Representative gel images. For each position
tested, the bottom panel (F) is the fluorescence image before staining
and the top panel (CB) is the image of the same gel after Coomassie
blue stain. Labeling of mutants containing Cys at the indicated site on
the background of CLAcrB in MG1655DacrB (lane C) or MG1655Da-
crABtolC (lane 1), and CLAcrBD407A in MG1655DacrB (lane 2). B. Relative
percentage of labeling for each site in acrABtolC knockout strain as
compared to acrB knockout strain (black), and in CLAcrBD407A as
compared to in CLAcrB (grey). Each experiment was performed three
times. The average value and standard deviation were shown. C.
Representative gel images of labeling in the absence (lane C) or
presence of over-expressed AcrA (lane 1) or TolC (lane 2). Gels were
labeled similarly as above.
doi:10.1371/journal.pone.0089143.g003
Figure 4. Cross-linking of AcrA with AcrB (1ane 1, WT) and
AcrBDloop (lane 2, Dloop). In the control sample (lane 3,/) the empty
vector was used in the transformation. The top and bottom panels are
representative blots detected using the anti-AcrA and anti-AcrB
antibodies, respectively.
doi:10.1371/journal.pone.0089143.g004
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proton relay pathway is intact, it is possible that translocation of
protons could still occur, which drove the conformational rotation.
Substrates could still migrate through the entire translocation
pathway in AcrB and then be release back into the periplasm. The
role of proton translocation in driving conformational rotation
necessary for labeling was confirmed by the observation that the
labeling of several sites was significantly weaker in AcrBD407A.
These sites include S134C, N274C, D276C, R620C, and E673C.
Since the D407A mutation has little effect on the overall structure
of AcrB and does not disrupt its interaction with AcrA and TolC,
it is reasonable to assume the observe decrease of labeling was a
result of defect in proton translocation.
We observed the most dramatic changes of labeling of the most
sites when AcrB was dissociated into monomers. While for some
residues including R717, T676, L668, F664, D566, and F666,
labeling in CLAcrBDloop was close to the level of labeling in
CLAcrB, for the rest of the sites tested labeling was much less in
CLAcrBDloop. Sites labeled the least in CLAcrBDloop as compared to
their levels of labeling in CLAcrB include Q89, N274, D276, and
E673. An inspection of their locations in the structure of AcrB
reveals that sites labeled to a level higher than 50% in CLAcrBDloop
relative to their levels of labeling in CLAcrB unanimously located
at the entrance and exposed sites of the external cleft, while sites
labeled much weaker in CLAcrBDloop located in the binding pocket
and the hidden part of the cleft (Figure 1B). The labeling results
indicated that substrates could still access the lower cleft and
external binding portal in monomeric AcrB, but could not enter
into the deep binding pocket. Furthermore, we found that the
interaction between AcrA and AcrB also depended on AcrB
trimerization, as the level of AcrA cross-linked with AcrBDloop was
much smaller than the amount cross-linked with wild type AcrB.
The Interacting region for AcrA could be located close to the
interface between two monomers of AcrB as it has been suggested
in the assembly model proposed by Symmons and coworkers [38].
We cannot completely eliminate the possibility that local
conformational change might have occurred in AcrBDloop and
affected its interaction with AcrA, although the circular dichroism
spectrum of AcrBDloop was very similar to that of the wild type
AcrB [28].
Results from this study allows us to speculate why AcrB function
as trimer. Trimerization is clearly required from the structural
aspect for AcrB to dock properly with the trimeric outer
membrane protein TolC. To investigate if each protomer in a
trimer could function independently, Nikaido and coworkers had
designed an elegant experiment to construct a covalently linked
trimer [39]. The covalent trimer is fully functional, but loses most
of its activity when the function of one protomer is disrupted. This
result suggests that the functions of protomers are coupled in a
trimer. Our result provided additional support for this picture. We
found that while substrate could still bind to exposed sites at the
entrance of the substrate translocation pathway, it failed to enter
the deep binding pocket. Trimerization of AcrB is likely required
to create three different and interlocked conformers in a functional
unit to channel substrate unidirectionally out of the cell [40].
Materials and Methods
Creation of Knockout Out Strains
Strains MG1655 (F-, l2, rph-1), BW25113 (F-, D (araD-
araB)567, DlacZ4787(::rrnB-3), l2, rph-1, D (rhaD-rhaB)568,
Table 1. MIC of BW25113DacrB strains containing plasmids encoding the indicated AcrB constructs and a summary of labeling
result.
AcrB construct MIC (mg/ml) Significant Change in Labeling?
erythromycin novobiocin Dloop D407A DacrAtolC
WT 80 160
/* 5 5
Entrance of the external cleft
F664C 20 40 No
F666C 40 10 No
L668C 80 80 No
R717C 5 10 No
Bottom of the cleft
D566C 10 10 No
E673C 80 160 Yes Yes No
T676C 80 80 No
Deep binding pocket
Q89C 80 160 Yes No No
S134C 80 160 Yes Yes No
F136C 80 160 Yes
N274C 80 80 Yes Yes**
D276C 80 160 Yes Yes**
F617C 40 40 Yes No No
R620C 80 80 Yes Yes No
*: Vector pQE70 was used to transform BW25113DacrB and used as the negative control.
**: According to reference 26.
doi:10.1371/journal.pone.0089143.t001
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hsdR514), and BW25113DacrB were obtained from the Coli
Genetic Stock Center (Yale University). Single MG1655DacrB
and combined MG1655DacrABTolC gene knockout strains were
created using Quick & Easy E. coli gene deletion kit (Gene
Bridges GmbH, Heidelberg, Germany) following the manufac-
turer’s protocol. In MG1655DacrB, acrB gene was replaced by a
kan resistance cassette. In MG1655DAcrABDTolC, the three
genes were knocked out in two steps. Gene tolC was knocked
out first followed by the removal of the kan resistance cassette
introduced to replace the tolC gene. In the second step, acrA and
acrB genes were deleted together following the same protocol.
Colony PCR was applied to confirm that target genes have
been knocked out.
Protein Purification
Plasmids pQE70-AcrB, pQE70-AcrBDloop, and the Cys-less
version pQE70-CLAcrB, pQE70-CLAcrBDloop were constructed in
a previous study [28]. They were transformed into E. coli
BW25113DacrB for protein expression under the basal condition
without induction. After grown overnight at 37uC with shaking,
cells were collected with centrifugation and then disrupted using
French press in a buffer containing 20 mM sodium phosphate
(pH 7.5), 0.2 M NaCl, 10% glycerol, and 1 mM phenylmethane-
sulfonyl fluoride (PMSF). The membrane fraction was collected
with ultra-centrifugation (100,0006g, 1 hour) and then solubilized
in phosphate buffer containing 1% (w/v) n-dodecylb-D-maltoside
(DDM). After centrifugation, protein in the supernatant was
purified using Ni-nitrilotriacetic acid (NTA) superflow resin as
described [28].
Fluorescent Labeling
The two intrinsic Cys in AcrB were first replaced with Ala to
create CLAcrB. CLAcrB has been shown by several studies to be
fully functional [29,41]. Using CLAcrB as the background, a single
Cys was introduced to replace each residue as indicated one at a
time. A thiol-specific fluorescent dye Bodipy-FL-maleimide was
used in labeling. Bodipy-FL-maleimide labeling was conducted
following the published method with slight modifications [26].
Briefly, BW25113DacrB, MG1655DacrB, or MG1655DacrABtolC
containing indicated plasmids were cultured overnight at 37uC
with shaking. Cells from 10 ml culture were collected through
centrifugation at 4,0006g for 5 min, washed twice using 10 ml of
phosphate buffer (50 mM potassium phosphate, 0.5 mM MgCl2,
pH 7.0), and resuspended in 5 mL of the same buffer. Cell density
was adjusted to OD660 of 3.5. Next, glucose and Bodipy-FL-
maleimide were added to the cells to final concentrations of 0.4%
and 6 mM, respectively. The mixture was shaken under room
temperature for 40 minutes (200 rpm). Cells were then collected
through centrifugation, washed with 5 ml phosphate buffer
containing 0.4% glucose, and then washed again with 5 ml
phosphate buffer.
Next, AcrB was purified as described with slight modifications
[26]. Briefly, cells were lysed by sonication in ice water bath and
centrifuged at 16,0006g for 20 minutes. The pellet was solubilized
in a phosphate buffer (50 mM sodium phosphate, 0.2 M NaCl,
10 mM imidazole, pH 8.0) containing 2% DDM on ice for 2
hours. The sample was then centrifuged under 16,0006g for 20
minutes and the supernatant was collected. AcrB was incubated
with Ni-NTA resins at 4uC for 2 hours with slow shaking. Resins
were then washed with a buffer containing 50 mM sodium
phosphate, 0.2 M NaCl, 40 mM imidazole, and 0.03% DDM
(pH 8.0). Finally the protein was eluted with a buffer containing
50 mM sodium phosphate, 0.2 M NaCl, 500 mM imidazole, and
0.03% DDM (pH 8.0).
To test labeling of AcrB mutants with the over-expression of
AcrA or TolC, plasmid pBAD33-AcrA or pBAD33-TolC were
co-transformed with pQE70-AcrBS134C or pQE70-AcrBN274C
into MG1655DacrB. The expression of AcrA or TolC was
induced with the addition of 0.2% arabinose during the
overnight incubation. Labeling was conducted as described
above.
Detection of the Labeling Signal
After protein purification, the eluted samples were resolved
using SDS-PAGE on 8% gels. To detect the fluorescence
labeling level by Bodipy-FL-maleimide, the gel was imaged
using Typhoon Phosphorimager, with an excitation filter
(488 nm) and an emission filter (510 nm). Then the gel was
stained using Coomassie Blue R250 and imaged under white
light. The intensities of the protein bands after staining revealed
the protein concentration in the different lanes. The two images
for each gel were analyzed and quantified using ImageJ [42].
The fluorescence intensity of each band was divided by its
intensity in Coomassie blue stain to adjust for small variations
in the quantity of sample loading. To determine the relative
level of labeling, the concentration normalized fluorescence
intensity for each site obtained in CLAcrBDloop was compared
with the concentration normalized fluorescence intensity ob-
tained in trimeric CLAcrB.
Chemical Cross-linking
Chemical cross-linking was performed as described [36,37].
Briefly, plasmid pQE70-AcrB, pQE70-AcrBDloop, or the empty
vector pQE70 was transformed into BW25113DacrB for protein
expression under the basal condition. Cells were then harvested
and treated with DSP. Extra DSP was quenched with a Tris
buffer before cells were collected and lyzed for protein
purification using Ni-NTA resin as described above. The eluted
protein was incubated with dithiothreitol (DTT) before resolved
using SDS-PAGE, followed by immunobloting with a polyclonal
anti-AcrA or anti-AcrB antibodies as the primary antibodies,
and an alkaline phosphatase-conjugated anti-rabbit antibody
(Abcam, Cambridge, MA) as the secondary antibody. The
protein-antibody conjugates were detected after staining using
nitroblue tetrazolium chloride and 5-bromo-4-chloro-39-indolyl
phosphate p-toluidine.
Drug Susceptibility Measurement
Activity of different AcrB constructs was determined by
measuring the MIC of BW25113DacrB containing plasmids
encoding each protein as described [28].
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